Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 16739 clinical trials
Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer

This is a Phase II treatment, non-randomized, open label clinical trial to study the efficacy of the Cetuximab when administered as single agent in recurrent/ metastatic head and neck squamous cell carcinoma after the failure or intolerance of immuno-oncology or immuno-oncology combined with chemotherapy.

recurrent head and neck squamous cell carcinoma
measurable disease
squamous cell carcinoma
cancer of the head
head and neck cancer
  • 0 views
  • 19 Feb, 2024
Adenoid Cystic Carcinoma and Carbon Ion Only Irradiation

So far, there is no data from Europe available for the sole irradiation with carbon ions. The present ACCO (Adenoid Cystic Carcinoma and Carbon ion Only irradiation) study, a prospective, open-label, phase II, single-arm, investigator-initiated study, will therefore investigate the sole radiotherapy of carbon ions in this tumor entity.

  • 0 views
  • 19 Feb, 2024
A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma

This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with persistent or recurrent endometrial carcinoma.

major surgery
plain x-ray
endocrine therapy
non-target
pleural effusions
  • 0 views
  • 19 Feb, 2024
Pembrolizumab Plus Paclitaxel Cisplatin Followed by Surgery for Locally Advanced ESCC

The purpose of this study is to observe and evaluate the efficacy and safety of pembrolizumab plus paclitaxel, cisplatin followed by Da Vinci robot radical surgery for locally advanced esophageal squamous cell carcinoma.

paclitaxel
pembrolizumab
pembrolizumab injection
squamous cell carcinoma
carcinoma
  • 0 views
  • 19 Feb, 2024
Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

This study is designed to assess the safety and efficacy of lenvatinib in combination with pembrolizumab versus standard of care (SOC) chemotherapy, and to also assess the safety and efficacy of lenvatinib monotherapy in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that have progressed after platinum …

paclitaxel
pembrolizumab
docetaxel
monoclonal antibodies
antihypertensive
  • 0 views
  • 19 Feb, 2024
Black Raspberry Nectar for the Prevention of Lung Cancer BE WELL Study

This trial studies how well black raspberry nectar works in changing the gut microbiome and in reducing inflammatory processes that may lead to lung cancer. Studying the effects of black raspberry beverage on inflammation may help doctors find strategies to reduce the risk of developing lung cancer.

lung carcinoma
vitamins
cancer
lung cancer
carcinoma
  • 0 views
  • 19 Feb, 2024
Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients

Phase 2 pilot study, which evaluates the safety and efficacy of Lutetium-177-PSMA radioligand therapy in advanced salivary gland cancer patients.

measurable disease
metastasis
adenoid cystic carcinoma
cancer
ct scan
  • 0 views
  • 19 Feb, 2024
Longitudinal Immune-phenotyping of HCC Following MK-3475

The study comprises a main study of pembro-treated HCC patients and a sub-study of untreated HCC patients. In the main study, patients will be treated with pembrolizumab as neoadjuvant treatment approximately 4 weeks prior scheduled surgery. Adjuvant treatment with pembrolizumab with commence at approximately 4 weeks post-surgery for up to …

hepatocellular carcinoma
pembrolizumab
hepatectomy
oncolytic virus therapy
serum bilirubin level
  • 0 views
  • 19 Feb, 2024
Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCC

Lenvatinib is the standard of care for patients with advanced hepatocellular carcinoma (HCC). The aim of the single-arm, open-label, phase II clinical trial is to assess efficacy and safety of lenvatinib as a preoperative conversion therapy in patients with potentially resectable HCC.

  • 0 views
  • 19 Feb, 2024
Esophageal Varices Prophylaxis in Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab

The goal of this prospective cohort study is to evaluate the progression of esophagogastric varices in patients treated with atezolizumab-bevacizumab. Assess the efficacy of primary prophylaxis of small esophageal varices with no risky signs and shortening endoscopic follow-up time intervals to reduce the risk of variceal hemorrhage.Researchers will assess the …

  • 0 views
  • 09 May, 2025